Recently, Barty Medical Technology (Zhejiang) Co., Ltd. announced the completion of a Series D financing round worth nearly RMB 200 million. The proceeds will primarily support the commercialization and further clinical evidence generation of its third-generation constrained drug-coated balloon products, the construction of a new intelligent manufacturing facility, and the development of next-generation vascular interventional devices.

Founded in 2015, Barty Medical is a vascular interventional medical device company headquartered in Hangzhou, China. The company has obtained 19 NMPA medical device registrations and developed a comprehensive product portfolio covering vascular access, vessel preparation and drug-based “leave-nothing-behind” interventional therapies.

One of the company’s flagship products is Matrix Super PTX®, a third-generation constrained drug-coated balloon designed for peripheral vascular interventions. The product aims to improve lesion preparation and targeted drug delivery while reducing the risk of vascular dissection after surgery. Barty Medical is also advancing additional innovative products for coronary and peripheral vascular applications.

Barty Medical’s products are currently available in more than 40 countries and regions. The latest financing round will further support the company’s manufacturing expansion, global clinical evidence development and international commercialization strategy, accelerating the global reach of China-developed vascular interventional technologies.